Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

Barnes, N., Qiu, Y., Pavord, I., Parker, D., Davis, P., Zhu, L., Johnson, M., Thomson, N. and Jeffery, P. (2006) Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine, 173(7), pp. 736-743. (doi:10.1164/rccm.200508-1321OC)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1164/rccm.200508-1321OC

Abstract

Rationale: No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease..

Objectives: We tested the hypothesis that inhaled combined long-acting β2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation.

Methods: Bronchial biopsies and induced sputum were taken from 140 current and former smokers (mean age, 64 yr) with moderate to severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 μg (n = 67) twice daily. Biopsies were repeated at 12 wk and sputa at 8 and 13 wk. After adjustment for multiplicity, comparisons between active and placebo were made for median change from baseline in the numbers of biopsy CD8+ and CD68+ cells/mm2 and sputum neutrophils..

Measurements and Main Results: Combination therapy was associated with a reduction in biopsy CD8+ cells of −118 cells/mm2 (95% confidence interval [CI], −209 to −42; p = 0.02), a reduction of 36% over placebo (p = 0.001). CD68+ cells were unaffected by combination treatment. Sputum differential (but not total) neutrophils reduced progressively and, at Week 13, significantly with combination treatment (median treatment difference, 8.5%; 95% CI, 1.75%–15.25%; p = 0.04). The combination also significantly reduced biopsy CD45+ and CD4+ cells and cells expressing genes for tumor necrosis factor-α and IFN-γ and sputum total eosinophils (all p ⩽ 0.03). These antiinflammatory effects were accompanied by a 173-ml (95% CI, 104–242; p < 0.001) improvement in prebronchodilator FEV1.

Conclusions: The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinflammatory effects in both current and former smokers with chronic obstructive pulmonary disease, which may contribute to clinical efficacy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Thomson, Professor Neil
Authors: Barnes, N., Qiu, Y., Pavord, I., Parker, D., Davis, P., Zhu, L., Johnson, M., Thomson, N., and Jeffery, P.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:American Journal of Respiratory and Critical Care Medicine
Publisher:American Thoracic Society
ISSN:1073-449X
ISSN (Online):1535-4970

University Staff: Request a correction | Enlighten Editors: Update this record